Alkem laboratories has provided an important update on its strategic acquisition as its wholly owned subsidiary Alkem Medtech Private Limited has executed the Share Purchase Agreement with selling shareholders of Occlutech Holding AG on March 6, 2026. This development represents the completion of the definitive agreement process that was previously announced.

Transaction Execution Details

Alkem Medtech Private Limited, the wholly owned Indian subsidiary of Alkem Laboratories, has successfully executed the Share Purchase Agreement with the selling shareholders of Occlutech Holding AG. This execution follows the earlier intimation provided to stock exchanges on February 13, 2026, regarding the intended acquisition.

Regulatory Compliance

The company has disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was communicated to both BSE Limited and National Stock Exchange of India Limited, ensuring full compliance with regulatory requirements.

Strategic Significance

This execution marks a crucial milestone in Alkem Laboratories' expansion strategy through its subsidiary. The acquisition of a majority stake ranging between 51% and 55% in the Switzerland-incorporated Occlutech Holding AG will provide significant operational control and strategic influence over the target entity. The transaction demonstrates the company's commitment to advancing its growth initiatives in the pharmaceutical and medical technology sectors.

Alkem Laboratories has announced that the United States Food and Drug Administration (USFDA) completed a Pre-Approval Inspection (PAI) at the manufacturing facility of its subsidiary Enzene Biosciences Limited in India. The inspection concluded with regulatory observations that require the company's attention and response.

USFDA Inspection Results

Following the completion of the inspection, the USFDA issued a Form 483 document containing specific observations about the facility's operations. The regulatory findings provide important insights into the inspection outcome and areas requiring attention.

Quality Systems Validation

A significant highlight of the inspection was Enzene's achievement of zero observations related to data integrity. The company emphasized this outcome as critical validation of Enzene's quality systems and the reliability of its regulatory filings. Data integrity represents a fundamental aspect of pharmaceutical manufacturing compliance and regulatory acceptance.

Corrective Action Response

Enzene Biosciences is actively preparing its formal response to address the USFDA observations. The subsidiary has initiated appropriate corrective and preventive actions to address the 6 procedural observations identified during the inspection. The company is working within the stipulated timeline to submit its comprehensive response to the regulatory authority.

Regulatory Compliance Framework

The Pre-Approval Inspection represents a standard regulatory process conducted by the USFDA to evaluate manufacturing facilities before approving pharmaceutical products. The Form 483 document serves as an official communication tool for conveying inspection observations that require company attention and response. Alkem Laboratories has formally notified stakeholders about this regulatory development as part of its compliance obligations under Regulation 30.